Join
Live feed
·
PRReleasevia Quantisnow
Cogent Biosciences Inc. logo

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

ByQuantisnow·Wall Street's wire, on your screen.
COGT· Cogent Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track COGT (Cogent Biosciences Inc.) and more on Quantisnow.